Fig. 3

Effects of NLRP3 and cas-1 inhibitors on c-cas-1, IL-1β, and N-GSDMD protein levels in the hippocampus of PISE mice. A and C. NLRP3 inhibitor MCC950 decreased c-cas-1 (A, Mann–Whitney U test, P < 0.01; C, independent-samples t test, t = 10.47, P < 0.01), IL-1β (A, independent-samples t test, t = 5.75, P < 0.01; C, independent-samples t test, t = 8.50, P < 0.01), and N-GSDMD protein levels (A, independent-samples t test, t = 5.98, P < 0.01; C, Mann–Whitney U test, P < 0.01) in the hippocampus of control and PISE mice. B and D. Cas-1 inhibitor Ac-YVAD-cmk decreased c-cas-1 (B, independent-samples t test, t = 5.04, P < 0.01; D, independent-samples t test, t = 9.50, P < 0.01), IL-1β (B, independent-samples t test, t = 5.91, P < 0.01; D, independent-samples t test, t = 11.54, P < 0.01), and N-GSDMD protein levels (B, independent-samples t test, t = 8.14, P < 0.01; D, independent-samples t test, t = 12.08, P < 0.01) in the hippocampus of control and PISE mice. E. Administration of MCC950 to PISE mice increased the numbers of surviving pyramidal neurons in the hippocampal CA1 (independent-samples t test, t = 10.01, P < 0.01) and CA2/3 area (independent-samples t test, t = 14.50, P < 0.01). Scale = 50 μm. ×10 objective for the middle column in E; ×40 objective for the left and right columns in E. ^{^^}P < 0.01 vs. control (ip.), ^<<P < 0.01 vs. control (icv.), ^##P < 0.01 vs. PISE + vehicle (ip.), ^&&P < 0.01 vs. PISE + vehicle (icv.)